MedTrace Logo

Cefuroxime Resistance in Pyelonephritis

NCT04616352 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 973

Last updated 2021-08-03

No results posted yet for this study

Summary

Resistance to empirical antibiotic treatment has resulted in increased mortality and morbidity in serious infections caused by certain common resistant pathogens in the community. The risk for increased mortality has been also the motivation for recent guidelines that suggest early empirical antimicrobial treatment with broad spectrum antibiotics within a few hours of suspecting sepsis, regardless of the potential microorganism or infection focus. Resistance to second-generation cephalosporins among patients with community-acquired urinary tract infection by E. coli has exceeded 20% in an increasing number of institutions and communities, without being clear about the impact of such resistance on the effectiveness of treatment. This is especially important in urinary infections, since, in general, mortality is very low. We expect to establish if there is a relationship between inappropriate empirical therapy and morbidity (in terms of length of stay or readmission) among hospitalized patients with pyelonephritis treated with empirical cefuroxime therapy to help to define the need for a change in the current guidelines. These guidelines will have application not only in Colombia, but also in other countries in Latin America or other countries that still use this empirical therapy. It will also define the need for use of broader spectrum antibiotics in this clinical scenario.

Conditions

Interventions

OTHER

Resistance to cefuroxime

Non susceptibility in vitro testing

Sponsors & Collaborators

  • Universidad Nacional de Colombia

    lead OTHER

Principal Investigators

  • Jorge A Cortes, MD · Univesidad Nacional de Colombia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-26
Primary Completion
2021-06-30
Completion
2021-07-30

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616352 on ClinicalTrials.gov